Literature DB >> 8416742

Expression of oligodendrocyte-associated genes in cell lines derived from human gliomas and neuroblastomas.

T Kashima1, S N Tiu, J E Merrill, H V Vinters, G Dawson, A T Campagnoni.   

Abstract

Two putative human oligodendroglioma cell lines were examined for the expression of the oligodendrocyte-associated genes, 2',3'-cyclic nucleotide-3'-phosphodiesterase, myelin basic protein, myelin proteolipid proteins, and myelin-associated glycoprotein. The expression of these genes also was examined in control astrocytoma and neuroblastoma cell lines. In addition, the expression of the non-oligodendrocyte-specific genes, glial fibrillary acidic protein (GFAP), neuron-specific enolase and neurofilaments (NF) NF-L and NF-M also were examined. All the cell lines expressed 2',3'-cyclic nucleotide 3'-phosphodiesterase, neuron-specific enolase, and vimentin, and none expressed myelin-associated glycoprotein. The "oligodendrocyte-specific" myelin proteolipid protein mRNAs and the "neuron-specific" NF-L mRNA were expressed in the two astrocytoma cell lines, which also expressed GFAP. Expression of intermediate filament protein genes was more restricted. The astrocytoma, neuroblastoma, and oligodendroglioma cell lines expressed only GFAP, NF-M, and cytokeratin K7, respectively. These results: (a) provide molecular data confirming the classification of the two cell lines as oligodendrogliomal and suggest that their molecular profiles are indicative of immature oligodendrocytes; (b) demonstrate the expression of cytokeratins in oligodendrogliomal cell lines and suggest that apparent GFAP expression in oligodendrogliomas detected by immunocytochemical methods may be due to cross-reactivity with cytokeratins, with which they share common polypeptide sequence; and (c) indicate that astrocytoma cell lines can exhibit a "mixed" phenotype, expressing genes associated with fully differentiated oligodendrocytes and neurons.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8416742

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

1.  Pituitary adenylyl cyclase-activating polypeptide stimulates DNA synthesis but delays maturation of oligodendrocyte progenitors.

Authors:  M Lee; V Lelievre; P Zhao; M Torres; W Rodriguez; J Y Byun; S Doshi; Y Ioffe; G Gupta; A E de los Monteros; J de Vellis; J Waschek
Journal:  J Neurosci       Date:  2001-06-01       Impact factor: 6.167

Review 2.  Intermediate filaments in the nervous system: implications in cancer.

Authors:  C L Ho; R K Liem
Journal:  Cancer Metastasis Rev       Date:  1996-12       Impact factor: 9.264

3.  Complement regulatory protein expression by a human oligodendrocyte cell line: cytokine regulation and comparison with astrocytes.

Authors:  P Gasque; B P Morgan
Journal:  Immunology       Date:  1996-11       Impact factor: 7.397

Review 4.  Pathology and molecular genetics of oligodendroglial tumors.

Authors:  Christian Hartmann; Wolf Mueller; Andreas von Deimling
Journal:  J Mol Med (Berl)       Date:  2004-10       Impact factor: 4.599

5.  The human myelin basic protein gene is included within a 179-kilobase transcription unit: expression in the immune and central nervous systems.

Authors:  T M Pribyl; C W Campagnoni; K Kampf; T Kashima; V W Handley; J McMahon; A T Campagnoni
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-15       Impact factor: 11.205

6.  Genetic aberrations in glioblastoma multiforme: translocation of chromosome 10 in an O-2A-like cell line.

Authors:  X Mao; T A Jones; I Tomlinson; A J Rowan; L I Fedorova; A V Zelenin; J I Mao; N J Gutowski; M Noble; D Sheer
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

7.  Reappraisal of Human HOG and MO3.13 Cell Lines as a Model to Study Oligodendrocyte Functioning.

Authors:  Kim M A De Kleijn; Wieteke A Zuure; Jolien Peijnenborg; Josje M Heuvelmans; Gerard J M Martens
Journal:  Cells       Date:  2019-09-17       Impact factor: 6.600

Review 8.  In vitro and in vivo pharmacological models to assess demyelination and remyelination.

Authors:  Jean E Merrill
Journal:  Neuropsychopharmacology       Date:  2008-09-17       Impact factor: 7.853

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.